Hormones and Cancer

, Volume 1, Issue 1, pp 55–62 | Cite as

Trends in Distant-Stage Breast, Colorectal, and Prostate Cancer Incidence Rates from 1992 to 2004: Potential Influences of Screening and Hormonal Factors



Differential utilization of cancer screening between populations could lead to changes in cancer disparities. Evaluating incidence rates trends is one means of monitoring these disparities. Using Surveillance, Epidemiology, and End Results data, we compared annual percent changes (APC) in age-adjusted incidence rates of distant-stage breast, colorectal, and prostate cancer between non-Hispanic whites (NHW) and African Americans (AA). From 1992 to 2004, distant-stage breast cancer incidence rates remained essentially constant among both AA and NHW women, though rates were 30–90% higher among AA women throughout. NHW men and women experienced declines in distant-stage colorectal cancer incidence rates [APC = −1.6, 95% confidence interval (CI) −2.3, −0.9], but AA men and women did not. Distant-stage prostate cancer incidence rates declined for both AA (APC = −5.8, 95% CI −7.9, −3.8) and NHW (APC = −5.1, 95% CI −6.7, -3.4). Despite now having nearly equal mammography screening rates, the persistent breast cancer disparity observed among AAs compared to NHWs may be due to the greater susceptibility of AAs to more aggressive tumors, particularly hormone-receptor-negative disease, which is more difficult to detect by mammography. For colorectal cancer, greater utilization of screening tests among NHWs vs. AAs is likely a primary contributor to the observed widening disparity. Wider recognition of AA race as a prostate cancer risk factor may contribute to the narrowing disparity in the incidence of disease.


Disparities Breast Colon Prostate Trends 


  1. 1.
    Boyer-Chammard A, Taylor TH, Anton-Culver H (1999) Survival differences in breast cancer among racial/ethnic groups: a population-based study. Cancer Detect Prev 23(6):463–473CrossRefPubMedGoogle Scholar
  2. 2.
    Bradley CJ, Given CW, Roberts C (2002) Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 94(7):490–496PubMedGoogle Scholar
  3. 3.
    Joslyn SA, West MM (2000) Racial differences in breast carcinoma survival. Cancer 88(1):114–123CrossRefPubMedGoogle Scholar
  4. 4.
    Shavers VL, Harlan LC, Stevens JL (2003) Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 97(1):134–147CrossRefPubMedGoogle Scholar
  5. 5.
    Cress RD, Morris CR, Wolfe BM (2000) Cancer of the colon and rectum in California: trends in incidence by race/ethnicity, stage, and subsite. Prev Med 31(4):447–453CrossRefPubMedGoogle Scholar
  6. 6.
    Chu KC, Tarone RE, Freeman HP (2003) Trends in prostate cancer mortality among black men and white men in the United States. Cancer 97(6):1507–1516CrossRefPubMedGoogle Scholar
  7. 7.
    Merrill RM, Lyon JL (2000) Explaining the difference in prostate cancer mortality rates between white and black men in the United States. Urology 55(5):730–735CrossRefPubMedGoogle Scholar
  8. 8.
    Jones BA, Liu WL, Araujo AB, Kasl SV, Silvera SN, Soler-Vila H et al (2008) Explaining the race difference in prostate cancer stage at diagnosis. Cancer Epidemiol Biomarkers Prev 17(10):2825–2834CrossRefPubMedGoogle Scholar
  9. 9.
    Elledge RM, Clark GM, Chamness GC, Osborne CK (1994) Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86(9):705–712CrossRefPubMedGoogle Scholar
  10. 10.
    Elmore JG, Moceri VM, Carter D, Larson EB (1998) Breast carcinoma tumor characteristics in black and white women. Cancer 83(12):2509–2515CrossRefPubMedGoogle Scholar
  11. 11.
    Li CI, Malone KE, Daling JR (2002) Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 11(7):601–607PubMedGoogle Scholar
  12. 12.
    Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502CrossRefPubMedGoogle Scholar
  13. 13.
    Powell IJ, Banerjee M, Sakr W, Grignon D, Wood DP Jr, Novallo M et al (1999) Should African–American men be tested for prostate carcinoma at an earlier age than white men? Cancer 85(2):472–477CrossRefPubMedGoogle Scholar
  14. 14.
    Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9(1):R6CrossRefPubMedGoogle Scholar
  15. 15.
    Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA et al (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91(23):2020–2028CrossRefPubMedGoogle Scholar
  16. 16.
    Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE et al (2005) A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14(5):1108–1112CrossRefPubMedGoogle Scholar
  17. 17.
    Rohrmann S, Sutcliffe CG, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G et al (2009) Racial variation in sex steroid hormones and the insulin-like growth factor axis in umbilical cord blood of male neonates. Cancer Epidemiol Biomarkers Prev 18(5):1484–1491CrossRefPubMedGoogle Scholar
  18. 18.
    Winters SJ, Brufsky A, Weissfeld J, Trump DL, Dyky MA, Hadeed V (2001) Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men. Metabolism 50(10):1242–1247CrossRefPubMedGoogle Scholar
  19. 19.
    Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW et al (1997) Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89(2):166–170CrossRefPubMedGoogle Scholar
  20. 20.
    Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, Feigelson H et al (1998) Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58(20):4497–4504PubMedGoogle Scholar
  21. 21.
    Travis RC, Schumacher F, Hirschhorn JN, Kraft P, Allen NE, Albanes D et al (2009) CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 18(10):2734–2744CrossRefPubMedGoogle Scholar
  22. 22.
    Ries LAG, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds) (2008) SEER cancer statistics review, 1975–2005. National Cancer Institute, BethesdaGoogle Scholar
  23. 23.
    Young J, Roffers S, Ries L, Fritz A, Hurlbut A (2001) SEER summary staging manual—2000: codes and coding instructions. National Cancer Institute, BethesdaGoogle Scholar
  24. 24.
    Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for Joinpoint regression with applications to cancer rates. Stat Med 19(3):335–351CrossRefPubMedGoogle Scholar
  25. 25.
    Harper S, Lynch J (2005) Methods for measuring cancer disparities: a review using data relevant to healthy people 2010 cancer-related objectives. National Institutes of Health, BethesdaGoogle Scholar
  26. 26.
    Anderson WF, Reiner AS, Matsuno RK, Pfeiffer RM (2007) Shifting breast cancer trends in the United States. J Clin Oncol 25(25):3923–3929CrossRefPubMedGoogle Scholar
  27. 27.
    Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL et al (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56(3):168–183CrossRefPubMedGoogle Scholar
  28. 28.
    Swan J, Breen N, Coates RJ, Rimer BK, Lee NC (2003) Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer 97(6):1528–1540CrossRefPubMedGoogle Scholar
  29. 29.
    Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA (2004) Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 101(7):1490–1500CrossRefPubMedGoogle Scholar
  30. 30.
    Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Marchbanks PA et al (2003) Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50–64 years. Cancer Epidemiol Biomarkers Prev 12(11 Pt 1):1175–1181PubMedGoogle Scholar
  31. 31.
    Chu KC, Tarone RE, Chow WH, Alexander GA (1995) Colorectal cancer trends by race and anatomic subsites, 1975 to 1991. Arch Fam Med 4(10):849–856CrossRefPubMedGoogle Scholar
  32. 32.
    Drake BF, Lathan CS, Okechukwu CA, Bennett GG (2008) Racial differences in prostate cancer screening by family history. Ann Epidemiol 18(7):579–583CrossRefPubMedGoogle Scholar
  33. 33.
    Wingo PA, Jamison PM, Hiatt RA, Weir HK, Gargiullo PM, Hutton M et al (2003) Building the infrastructure for nationwide cancer surveillance and control—a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control 14(2):175–193CrossRefPubMedGoogle Scholar
  34. 34.
    Clegg LX, Reichman ME, Hankey BF, Miller BA, Lin YD, Johnson NJ et al (2007) Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. Cancer Causes Control 18(2):177–187CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  1. 1.Department of EpidemiologyUniversity of Washington School of Public HealthSeattleUSA
  2. 2.Division of Public Health SciencesFred Hutchinson Cancer Research CenterSeattleUSA

Personalised recommendations